论文部分内容阅读
目的探讨阿德福韦酯对乙型肝炎病毒e抗原(HBe Ag)阴性慢性乙型肝炎患者外周血T细胞亚群的影响。方法对2012年5月-2013年5月56例慢性乙型肝炎患者常规给予护肝治疗,同时给予口服阿德福韦酯10 mg,1次/d,疗程48周。检测服药前及48周后肝功能、乙型肝炎病毒(HBV)DNA及T细胞亚群。结果经口服阿德福韦酯治疗48周后,患者血清HBV-DNA滴度较治疗前明显下降,肝功能明显改善,CD 4+T淋巴细胞百分比(37.3%)较治疗前(32.8%)明显升高(P<0.001),CD 4+/CD 8+(1.37)较治疗前(1.11)升高(P<0.005)。结论阿德福韦酯治疗HBe Ag阴性慢性乙型肝炎,在抑制HBV的复制、减轻肝脏炎症反应的同时,也可能改善了慢性乙型肝炎患者的细胞免疫功能。
Objective To investigate the effect of adefovir dipivoxil on T lymphocyte subsets in peripheral blood of patients with chronic hepatitis B due to hepatitis B virus e antigen (HBeAg). Methods From May 2012 to May 2013, 56 patients with chronic hepatitis B were treated routinely with liver protection and oral adefovir dipivoxil 10 mg once daily for 48 weeks. Liver function, hepatitis B virus (HBV) DNA and T cell subsets were measured before and 48 weeks after treatment. Results After 48 weeks of treatment with adefovir dipivoxil, the serum HBV-DNA titer in patients was significantly lower than before treatment, and the liver function was significantly improved. The percentage of CD 4 + T lymphocytes (37.3%) was significantly higher than that before treatment (32.8%) (P <0.001). CD 4 + / CD 8+ (1.37) was higher than that before treatment (1.11) (P <0.005). Conclusion Adefovir dipivoxil treatment of HBeAg-negative chronic hepatitis B, in inhibiting HBV replication, reduce liver inflammation, but also may improve the cellular immune function in patients with chronic hepatitis B.